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Abstract
Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its 
carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into 
the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-
induced mutations affect comparable signaling pathways such as RB restriction of cell cycle 
progression or p53 inactivation. Despite its low incidence, MCC recently received much attention 
based on its exquisite immunogenicity and the resulting major success of immune modulating 
therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC 
as conclusion of the project ‘Immune Modulating strategies for treatment of Merkel Cell 
Carcinoma’, which was funded over a 5-year period by the European Commission to investigate 
innovative immunotherapies for MCC.
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Introduction
Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of 
the skin. The majority of cases is associated with the recently discovered common Merkel 
cell polyomavirus (MCPyV) while the remaining are triggered by UV-mediated mutations 
[1]. With an incidence of 0.6 per 100,000 per year in the US in 2009 (US Standard 
Population) MCC is a very rare cancer [1]. Although MCC is 40 times less common than 
malignant melanoma, MCC has a dramatically lower survival probability than melanoma, 
rendering MCC the most lethal skin cancer. Indeed, epidemiologic data suggest that there 
are approximately 2500 new MCC cases per year within the European Union (EU), and 
approximately 1000 of these patients will die from their disease [2]. This high mortality rate 
is largely due to the fact that until recently none of the standard therapeutic interventions 
was able to improve overall survival of patients suffering from metastatic disease. Since 
several lines of evidence indicate the outstanding immunogenicity of MCC, immune 
modulating treatment strategies are particularly attractive.
IMMOMEC was a 5-year project to establish and investigate an innovative immunotherapy 
for MCC which is based on the targeted delivery of interleukin-2 to the tumor 
microenvironment. However, fortunately for the patients, but unfortunately for the 
IMMOMEC trial, the advent of immune checkpoint-inhibiting antibodies [specifically the 
programmed death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) blocking 
antibodies, pembrolizumab and avelumab, respectively] revolutionized the treatment of 
advanced MCC [3, 4]. Indeed, these agents achieve durable objective response rates of up to 
50% of the treated patients. Thus, the bar for any new therapeutic, particularly 
immunotherapeutic, to be tested in advanced MCC had been raised high [5]. As a 
consequence, the initial recruitment into the IMMOMEC trial was substantially slowed by 
the fully sponsored competing trials using checkpoint inhibitors, and once their strong 
clinical efficacy had been reported the recruitment rate virtually ceased. However, 
IMMOMEC was not only testing a new therapeutic option for MCC patients, but also aimed 
at establishing and validating new tools to monitor patients receiving immunotherapies as 
well as compile prognostic and predictive biomarkers to individualize immune modulating 
therapies [6–15].
The epidemiology of Merkel cell carcinoma
A comprehensive analysis of time trends of the population-based incidence of MCC is 
complicated, considering that MCC was first described in 1972 and had many synonyms. In 
addition, in its first edition the International Classification of Diseases for Oncology (ICD-
O) (1976–1989) did not contain specific morphology codes for MCC. The second edition of 
ICD-O, released in 1990, introduced the codes M8246/3 (neuroendocrine carcinoma) and 
M8247/3 (MCC) [16]. Hence, reliable time trends should have starting times after 1990. 
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Analyses of more than 100 regional or national population-based cancer registry data sets on 
MCC identified more than 19,000 cases for the period from 2003 until 2007, and more than 
12,000 cases for the time trend analysis of the years 1990 through 2007 (A. Stang, 
unpublished data). Several cancer registries demonstrated incidence rates of MCC in the 
early 1990s (1990–1994) that were close to zero, indicating unreliable incidence registration. 
Importantly, since the mid of the 1990s, the registries of US SEER White, Canada, 
Australia, The Netherlands, and Italy revealed an increase of MCC incidence. Age-
standardized incidence rates (World Standard Population) of the period from 2003 until 2007 
were highest in Australia (men: 5.2 per million person years; women: 2.2 per million person 
years).
Cell of origin of Merkel cell carcinoma
The cellular origin of MCC is still controversial. Initially, the favored theory was that MCC 
originates from Merkel cells. However, because normal Merkel cells are terminally 
differentiated and do not undergo cell division, they probably are not the cell of origin for 
MCC. Thus, this notion was followed by the hypothesis that a Merkel cell precursor, for 
example, epidermal or dermal stem cells, is the possible cell of origin of MCCs [17]. Still it 
is important to note that the majority of MCCs develop in a spatially distant Merkel cell-free 
micro-anatomic compartment of the skin. Based on the finding of concomitant expression of 
paired box 5 (PAX-5), Terminal deoxynucleotidyl transferase (TdT) and diverse 
immunoglobulins, including monoclonal IgH and Igk rearrangement in MCC cells, which is 
normally restricted to early B cells, it was postulated that pre-/pro-B cells might constitute 
the cellular origin of MCCs [18]. The suggested interpretation of MCC as a cutaneous 
manifestation of a highly malignant pre-/pro-B cell neoplasia would allow a different 
understanding of the diverse pathological and clinical features of MCC [19, 20]. However, to 
date none of these cells could be transformed by the expression of the MCPyV-encoded T 
antigens in vitro. Notably, human dermal fibroblasts support productive MCPyV infection 
[21]. Induction of genes encoding matrix metalloproteinases by the WNT/β-catenin 
signaling pathway stimulated MCPyV infection, suggesting that UV radiation and aging 
(that is, well established risk factors for MCC), which are known to stimulate WNT 
signaling and matrix metalloproteinases expression, could promote MCPyV infection of 
fibroblasts and, therefore, drive MCC development [21]. Identification of the cell of origin 
together with an improved understanding of the mechanism of viral carcinogenesis might 
also enable the identification of susceptibility factors for MCPyV-driven MCC 
carcinogenesis.
Elucidating the role of MCPyV-encoded oncoproteins in transformation
The human tumor virus MCPyV establishes lifelong persistent infections in ~ 90% of the 
healthy human population, and is the leading cause of MCC [22]. A number of observations 
suggest that the virus is causally linked to MCC tumorigenesis. For example, viral sequences 
are monoclonally integrated into the tumor cell genome, i.e. in MCPyV-positive cases the 
virus has the identical integration sites in the primary tumor and the respective metastases. 
Furthermore, expression of the early viral proteins, i.e. the T antigens consisting of small T-
Antigen (sT) and large T-Antigen (LT), can be detected in tumor tissues [23–26]. While both 
sT and LT are necessary for maintaining the oncogenic phenotype of MCPyV+ MCC cell 
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lines, sT appears to be more potent in transforming model cell lines such as rodent fibroblast 
cell lines [27–29]. It should be further noted that all LT sequences recovered from primary 
MCC tumors or MCC cell lines harbour signature mutations resulting in the expression of 
shortened LTs. These truncation products always retain the retinoblastoma protein (RB)-
binding motif, but lack the C-terminal region that is required for viral replication and—as 
deducted from SV40 LT—supposedly binding of p53. Recently, it was also demonstrated 
that truncated LT proteins not only exhibit an increased binding affinity for RB, but are also 
able to partially re-localize RB to the cytoplasm. This notion suggest additional properties of 
the tumor-derived truncated LT compared to the wild-type protein and a major importance 
role of its RB-binding capacity in MCC tumorigenesis [30] (Fig. 1).
To understand early events of viral integration and cellular transformation, an in vitro 
MCPyV replication model was developed which will allow to mimic these early events of 
virus-induced transformation [23, 26]. To understand MCC pathogenesis and in particular 
MCC metastasis formation, a spontaneous metastasis xenograft mouse model was used. 
Applying genome-wide transcriptome analyses of the xenograft tumors arising from 
transplanted MCC cell lines, it was demonstrated that several MCC cell lines are well suited 
to study metastasis formation of MCC tumors in a xenograft (severe combined 
immunodeficiency) SCID mouse model system [42]. This model will significantly 
contribute to elucidate the virally mediated mechanisms in metastasis formation.
Functions of large T antigen in MCC cells
MCC cells harboring MCPyV are dependent on the expression of the viral T antigens, i.e. sT 
and LT. Previous studies demonstrated that knockdown of T antigens in MCC cells impairs 
their growth [25]. This effect can be rescued by ectopic expression of an shRNA-insensitive 
LT. Consequently, modifying this ectopically expressed LT allows identifying domains or 
regions required for the growth-promoting function of LT. To this end, experiments with 
mutated LTs demonstrated, that the HSC70 as well as pocket protein (PP)-binding domains 
are required for the growth-promoting functions of LT [43]. In addition, for proper function 
of LT the protein has to enter the nucleus, which, however, is independent of the nuclear 
localization sequence (NLS) reported to be at position 177–180. Phosphorylation of serine at 
position 220 was identified as a post-translational modification required for the oncogenic 
function of truncated LT [38]. A recent study aiming at the identification of the cellular 
interaction partner(s) for the PP-binding domain of LT identified the three PP family 
members RB1, p107 and p130 as the main candidates. Knockdown of these individually 
demonstrated that knockdown of RB1 alone was sufficient to rescue the effect of LT 
knockdown-mediated cellular growth impairment [44] (Fig. 1). Thus, in contrast to other 
polyomavirus LTs, which interact with all three PP family members, for MCPyV’s LT RB1 
is the predominant cellular partner.
Does sunlight and MCPyV target the same pathways in MCC?
Virus-positive MCC tumors express MCPyV sT and a truncated MCPyV LT, which both 
bind to multiple proteins thereby altering their functions. A comprehensive, yet not 
exhausting overview of these interactions are depicted in Fig. 1. It should be noted that full 
length LT—as deducted from SV40 LT—supposedly binds to p53, whereas the truncated 
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form expressed in MCC does not. These functions, however, are not sufficient to promote 
oncogenesis [45]. In contrast, virus-negative MCCs are characterized by high frequencies of 
UV-induced DNA damage with mutations that inactivate the RB1 and p53 genes [46]. It was 
recently demonstrated that MCPyV sT specifically recruits L-myc-1 proto-oncogene protein 
(MYCL) and myc-associated factor X (MAX) to the 15-component p400 complex. sT, 
MYCL and the p400 complex bind specifically to transcription start sites and promote gene 
expression [37]. Wild-type sT, but not a p400 binding mutant, can cooperate with MYCL to 
transform human fibroblasts. sT-MYCL-p400 can increase expression of Mouse double 
minute 2 homolog (MDM2), which contributes to the inactivation of the p53 pathway (Fig. 
1). These results demonstrate that MCPyV sT recruitment of MYCL to the p400 complex 
contributes to MCC oncogenesis and provides insights into the function of MYC in 
malignant transformation.
Genomic and immune heterogeneity in non-viral Merkel cell carcinoma
While MCPyV can be detected in up to 80% of MCC cases in the northern hemisphere, its 
presence is much lower in other geographic regions such as Australia (~ 30%) [1]. MCPyV-
negative, aka non-viral, MCC appears to be a distinct entity with hallmarks of a high 
mutation load caused by UV-damage [47]. Excessive sun-exposure is, therefore, the 
predominant risk factor for the development of non-viral MCC (Fig. 2a). Despite clear 
genetic differences between viral and non-viral MCC, immune escape is likely to be 
important for both groups, as viral-antigen or mutation-associated neoantigens are potent 
immunogenic stimuli. Importantly, immune checkpoint therapies involving the PD-1/PD-L1 
axis have recently been shown to be effective in both viral and non-viral subtypes of MCC, 
thereby offering a promising treatment strategy for advanced disease [3, 4]. Considering that 
checkpoint-based immunotherapy will not be effective for all MCC patients, it is important 
to have a better understanding of cellular and genomic determinants of the immune 
response. By characterizing non-viral MCC based on a framework of immune reactivity 
within the tumor microenvironment, MCC tumors can be classified into two groups based on 
the frequency of tumorinfiltrating lymphocytes (TIL) and PD-L1 expression, i.e. type 1 
“immune resistant” (high TIL/high PD-L1) and type 2 “immune ignorant” (low TIL/low PD-
L1). Mutation burden is higher in type 1 non-viral MCC, consistent with the notion that a 
higher neoantigen load exists within more densely infiltrated tumors [47–53] (Fig. 2b). 
However, there are also individual exceptions to this rule, suggesting that other factors can 
influence the immune response. An additional level of complexity is added by the intra-
patient heterogeneity between metastatic lesions. Such a heterogeneity not only explains the 
potential difficulty to identify predictive biomarkers from a single biopsy, but also that 
heterogeneous responses to immune checkpoint blockade have to be expected.
Novel tools to gain insights into T-cell responses to MCC
Discovery of CD8+ T-cell epitopes in MCC is important for understanding the immune 
recognition of cancer cells. This cellular component plays a major role in mediating tumor 
cell eradication, and can be utilized in T cell-based immunotherapeutic strategies. To this 
end, current state-of-the-art strategies use combinatorial encoding of fluorescence-labeled 
peptide–MHC multimers. With this strategy, 56 T-cell recognitions towards 35 different 
MCPyV-derived peptides were detected in a cohort of 38 MCC patients. T-cell responses 
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towards LT and sT antigens were solely detected in cancer patients compared to healthy 
donors [11]. However, a major limitation to this strategy is the maximum number of peptide 
specificities (< 36) to be screened for in a single sample. Accordingly, screening for a large 
peptide library will thus require a large amount of patient material. To address this problem, 
a novel technology with DNA barcode-labeled peptide-MHC multimers to increase the 
possibly covered complexity has recently been introduced [54]. This technology uses an 
oligonucleotide to form a barcode tag that is associated to the identity of a given peptide–
MHC complex, allowing the mixing of > 1000 T-cell specificities. After selection of MHC 
multimer-binding T cells, the specificity can be revealed by sequencing the attached 
barcode. A correlation with the current state-of-the-art strategies revealed a similar 
sensitivity coupled with a significantly better detection of low-avidity T-cell populations. 
Using this novel technology when screening for cancer-specific T cells, a high-throughput 
platform for epitope mapping with less demand of patient material has been created.
Loss of non-classical MHC molecules is an immune escape mechanism of MCC
Viral infection as well as malignant transformation are well-known inducers of MHC class I 
chain-related protein (MIC) A and B expression. These ligands signal stress to immune 
cells, resulting in the elimination of target cells via a natural killer group 2D (NKG2D) 
receptor-dependent mechanism [55]. Interestingly, despite the malignant nature of MCC 
cells, the viral infection with the Merkel cell polyomavirus (MCPyV) and the permanent 
expression of virally encoded genes, MICs are not expressed in the majority of MCC 
tumours in situ, and are completely lacking on MCC cell lines in vitro [8]. This absence of 
MIC expression in MCC is mediated by epigenetic silencing of gene transcription in the 
MIC promoter region via histone hypo-acetylation. However, MIC expression is re-inducible 
by inhibition of histone deacetylases (HDACs) with an FDA (Food and Drug 
Administration)-approved HDAC inhibitor in vitro, as well as in vivo. Moreover, the re-
induction of MICs on MCC cells results in an increased sensitivity towards immune cell-
mediated lysis [8] (Fig. 2c). These findings demonstrate that epigenetic silencing of MICs is 
an essential immune escape strategy of MCCs, and that epigenetic priming with HDAC 
inhibitors could consequently increase the effectiveness of immunotherapeutic approaches 
towards MCC. It should be noted that polyomavirus infection may also use other epigenetic 
mechanisms to downregulate NKG2D ligands, e.g. a viral miRNA identical in sequence 
between John Cunningham virus (JCV) and B.K. Virus (BKV) targets the NKG2D ligand 
UL16 binding protein 3 (ULBP3) [56].
Progress and problems on the road to immunotherapy for Merkel cell carcinoma
The observation that antibodies to the MCPyV oncoprotein fluctuate with disease burden is 
the basis for a blood test to detect early recurrence [57]. This test has recently been validated 
in a prospective cohort of several hundred patients. It appears to be useful for all MCC 
patients because it separates them into two distinct groups. The first group consists of 
patients not producing these antibodies, which need to be followed-up closely with imaging 
studies as they are at a 42% higher risk of recurrence than antibody-positive patients. The 
second group of patients who produce these antibodies can be followed-up with this blood 
test as dropping antibody titers correlate with an improved prognosis and increasing titers 
indicate reoccurrence of the disease [57] (Fig. 3a).
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Recent clinical trials indicate that PD-1 blockade leads to clinical responses in > 50% of 
patients with advanced MCC when treated in first line (no prior chemotherapy) [4]. For 
patients who previously received chemotherapy, the response rate is lower, but still 
significant with about 30% [3] (Fig. 3b). Diverse efforts are ongoing to determine predictors 
of whether a patient will respond to PD-1 pathway blockade or not, as well as how to treat 
patients who do not respond [5]. In addition to the properties of the tumor cells itself, the 
tumor microenvironment strongly modulates immune responses to solid cancers and thus 
contributes to a possible immune escape [58].
MCC research needs a multidisciplinary clinical and translational research program
The inception of a multidisciplinary MCC program at the University of Michigan in 2006 
attracts approximately 80 new patients with all stages of MCC annually, i.e. accounting for 
about 5% of all patients diagnosed with MCC in the US. This allowed enrollment of more 
than 600 MCC patients into a prospective clinical database, establishment of an extensive 
tumor repository and development of a robust translational research program [59]. Clinical 
data and expertise from this large MCC center have contributed to the development of the 
new 8th edition American Joint Committee on Cancer (AJCC) MCC staging system [60]. 
This revised staging system will include a separate stage group for patients with metastatic 
MCC with unknown primary tumor, who carry a more favorable prognosis compared to 
patients presenting with concurrent primary and nodal metastatic disease. Consistent clinical 
management according to a previously established treatment algorithm in addition to 
multidisciplinary care through tumor board consensus has demonstrated the importance of 
sentinel lymph node biopsy in patients with stage I and II MCC. It also allowed to identify 
low-risk primary tumors for which adjuvant radiation therapy to the primary tumor bed can 
safely be omitted [61].
Similarly, there is a prospective biobank for MCC patients comprising tumor cell lines, 
tumor tissue, peripheral blood lymphocytes, plasma and serum, as well as an online clinical 
data bank on MCC patients from German speaking countries. The latter is hosted by the 
German Dermato-Oncology Cooperative Group (DeCOG/ADO; http://www.ado-
homepage.de/merkelzellkarzinom-register.html). Operation of the biobank, with respect to 
establishing and characterizing tumor cell lines, benefits from experience with ESTDAB 
(European Searchable Tumour Cell and Data Bank) and OISTER (Outcome and Impact of 
Specific Treatment in European Research on Melanoma) two previous projects funded by 
the European Commission (https://www.tati-group.de/tati-projects/estdab/).
Conclusion
The increased understanding of the epidemiology, biology and immunology of MCC, which 
at least in part was spurred by the IMMOMEC project funded by the European Commission, 
allowed a more personalized therapy of MCC improving the lifespan and quality of life for 
the concerned patients and their relatives. Albeit, the IMMOMEC clinical trial was not as 
successful as hoped for, the IMMOMEC project and its consortium paved the way for future 
collaborative research within and well beyond the borders of Europe. Moreover, aided by the 
preparatory work within the IMMOMEC Project, it was possible to launch the first 
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prospectively randomized adjuvant trial for MCC, which of course is based on an immune 
modulating intervention (checkpoint inhibition versus observation; EudraCT 
2013-000043-78; ADMEC).
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Fig. 1. 
Domains and functions of MCPyV T antigens. a sT can (i) preserve 4E-BP1 
hyperphosphorylation resulting in dysregulated cap-dependent translation [31], (ii) through 
inhibition of SCF Fbx7 ubiquitin ligase stabilize their cellular targets and MCPyV LT [32], 
(iii) interact with NEMO thereby inhibiting NF-κB-mediated transcription [33–35], (iv) lead 
to a motile and migratory phenotype by promoting microtubule destabilization [36], (v) 
elevate aerobic glycolysis by regulating MCT-1 levels [37] and (vi) inactivate p53 pathway 
through recruitment of MAX and MYCL and binding to P400 complex resulting in 
increased expression of the p53 inhibitor MDM2. b In tumor cells, the C-terminal domains 
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of LT containing several crucial elements required for viral replication are consistently 
truncated by tumor-associated mutations. The truncated LT can (i) mediate cell proliferation 
by binding RB1 [38], (ii) lead to gene expression alterations most of which require an intact 
RB binding site [39], (iii) disrupt lysosomal clustering by binding hVam6p and translocating 
it into the nucleus [40] and (iv) interact with Brd4 to RFC to the viral replication sites 
facilitating replication [41]. The latter two functions seem to be relevant for the normal life 
cycle of the virus. 4E-BP1 = eukaryotic translation initiation factor 4E-binding protein 1; 
SCF = the Skp1-Cul1-F-box protein; FBx7 = F-box protein 7; NEMO = NF-κB essential 
modulator; MCT-1 = monocarboxylat-Transporter 1; hVamp6 = human VAM-encoded 
protein; 6Brd4 = bromodomain protein 4; RFC = recruit replication factor C
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Fig. 2. 
Immunogenicity of MCC. a MCCs can be divided upon their association with MCPyV. For 
both, viral and non-viral MCCs, the cell of origin has not yet been identified and, 
consequently, it is currently not known if they originate from the same cell. Although 
transformation is caused by the virus or by UV-induced mutations, they both lead to RB and 
p53 pathway inactivation. Immunogenicity of both tumors is high due to presentation of 
viral peptides or neoantigens, respectively [47]. b Based on programmed death-ligand 1 
(PD-L1) expression and immune infiltrate, non-viral MCC cases can be divided into 
immune-resistant or immune-ignorant tumors. The latter demonstrate a lower mutagenic 
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burden [47]. c MCC tumors present with a low/absent expression of the stress molecules 
MHC class I polypeptide-related sequence A and B (MICA/B). Treatment of MCC cells 
with histone deacetylases leads to induction/increased expression of MICA/B [8]. These 
natural killer group 2D (NKG2D) ligands act co-stimulatory on T cells and activate on NK 
cells. Consequently, the lysis of tumor cells by immune cells is increased after histone 
acetylase inhibition
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Fig. 3. 
Blood-based biomarkers and immunotherapy. a Determination of antibody reactivity against 
sT in serum of MCC patients. Seropositivity at the time point of diagnosis is not only 
associated with a reduced risk of recurrence, but can be used diagnostically. To this end, a 
falling (< 20% to last sample) or negative titer has a negative predictive value of 97%, while 
rising titers (> 20%) has a positive predictive value of 66% for the occurrence of recurrence 
[57]. b Interfering with the programmed cell death protein 1/programmed death-ligand 1 
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(PD-1/PD-L1) signaling pathway by inhibitory antibodies achieve response rate of > 50% in 
the first line setting and about 30% in patients previously treated with chemotherapy [3, 4]
Becker et al. Page 18
Cancer Immunol Immunother. Author manuscript; available in PMC 2018 June 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
